Stealth biotech bags rights to VelaVigo bispecific in $440M deal
Title
Stealth Biotech Secures Rights to VelaVigo's Bispecific Antibody in $440M Deal
Keywords
- Stealth biotech
- VelaVigo
- Bispecific antibody
- Ollin Biosciences
- Licensing deal
- Drug development
- China biotech
- Ex-China rights
- $440 million
- Biotech partnerships
Key Facts
- VelaVigo, a China-based biotech startup, has signed its second major deal with a US biotech company, highlighting increased cross-border activity in drug development135.
- In this latest agreement, VelaVigo is licensing out ex-China rights to a preclinical bispecific antibody to Ollin Biosciences, a "stealth" or little-known biotech company, for up to $440 million135.
- The deal covers the rights to develop and commercialize the bispecific antibody outside of China, emphasizing VelaVigo's global partnership strategy13.
- This marks a notable step for VelaVigo toward international expansion and validates its antibody discovery platform15.
- The $440 million headline figure includes upfront, milestone, and potential future payments, typical for licensing deals at the preclinical stage1.
- The agreement underlines the continued interest from US biotechs in accessing innovative assets from China’s growing biotech sector135.
Sources:
1. https://endpts.com/china-based-velavigo-inks-its-second-us-biotech-deal/